期刊
JOURNAL OF CONTROLLED RELEASE
卷 343, 期 -, 页码 620-644出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2022.02.009
关键词
Experimental autoimmune encephalomyelitis; (EAE); Immune response; Multiple sclerosis (MS); Nanoparticles; Nanotechnology; Tolerance
Multiple Sclerosis is an autoimmune disease that can be effectively managed through the use of nanoparticles, which support early detection and therapeutic treatment.
Multiple Sclerosis (MS) is an autoimmune disease with complicated immunopathology which necessitates considering multifactorial aspects for its management. Nano-sized pharmaceutical carriers named nanoparticles (NPs) can support impressive management of disease not only in early detection and prognosis level but also in a therapeutic manner. The most prominent initiator of MS is the domination of cellular immunity to humoral immunity and increment of inflammatory cytokines. The administration of several platforms of NPs for MS management holds great promise so far. The efforts for MS management through in vitro and in vivo (experimental animal models) evaluations, pave a new way to a highly efficient therapeutic means and aiding its translation to the clinic in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据